Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 100 #1
CompanyRuckus Wireless, Inc.
IndustryComputer Based Systems
Market Cap1.20BEPS (ttm)0.03
P/E483.00EPS this Y-91.70%
Forward P/E25.16EPS next Y44.72%
PEG27.87EPS past 5Y0.00%
P/S4.02EPS next 5Y17.33%
P/B5.29EPS Q/Q100.00%
Dividend-Sales Q/Q26.80%
Insider Own1.60%Inst Own66.00%
Insider Trans-36.83%Inst Trans6.40%
Short Float8.60%EarningsJul 30/a
Analyst Recom2.30Target Price15.82
Avg Volume1.38M52W Range8.65 - 18.58
16-Sep-14 09:15AMBarracuda Joins Ruckus Wireless Technology Ecosystem Program PR Newswire
12-Sep-14 12:46PMFlexion Therapeutics Keeps Climbing at TheStreet
09-Sep-14 09:08AMMoving Average Crossover Alert: Ruckus (RKUS) Zacks
08-Sep-14 09:41AMCan the Rally in Ruckus (RKUS) Shares Continue? Zacks
08-Sep-14 09:00AMRuckus Introduces SWIPE--the Smart Wireless Installation and Provisioning Engine for Smart WLANs PR Newswire
03-Sep-14 08:08AM[video] Top tech picks at CNBC
27-Aug-14 04:05PMRuckus Wireless To Present at Upcoming Investor Conferences PR Newswire
20-Aug-14 09:00AMRuckus Wireless Again Takes Top Marks in CRN's Prestigious Annual Report Card (ARC) Survey of Value-Added Resellers PR Newswire
13-Aug-14 07:26AMWhy Ruckus Wireless (RKUS) Could Be Positioned for a Surge? Zacks
08-Aug-14 01:04PMRUCKUS WIRELESS INC Financials EDGAR Online Financials
Ruckus Wireless, Inc. provides carrier-class Wi-Fi solutions to service providers and enterprises worldwide. It provides gateways, controllers, and access points with related software and services. The company offers SmartCell Gateway, a carrier-class platform to support and manage its Smart Wi-Fi access points, as well as for the integration of Wi-Fi and other services into service provider network infrastructure; SmartCell access points that enables service providers to deploy networks within urban environments; and ZoneDirector Smart WLAN controllers that streamline the configuration and management of its access points. It also provides ZoneFlex access points, which support various virtual WLANs, Wi-Fi encryption, and advanced traffic handling, as well as ZoneFlex outdoor Smart Wi-Fi access points, and point-to-point and multipoint bridges. In addition, the company offers software products, such as FlexMaster, a software-based Wi-Fi management service platform for monitoring and administering networks, as well as technical support and maintenance services. It serves enterprise end-customers of mid-sized organizations in various industries, including hospitality; education; healthcare; warehousing and logistics; corporate enterprise; retail; state and local governments; and public venues, such as stadiums and convention centers, airports, and outdoor public areas, as well as serves a range of service providers comprising mobile operators, cable companies, wholesale operators, and fixed-line carriers. The company was formerly known as Video54 Technologies, Inc. Ruckus Wireless, Inc. was incorporated in 2002 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kish William S.A.Chief Technology OfficerSep 18Sale14.47150,0002,171,1451,079,721Sep 19 09:39 PM
MAYNARD DENISV.P.Sales and Field OperationsSep 15Option Exercise2.1837,00080,72066,500Sep 17 05:14 PM
MAYNARD DENISV.P.Sales and Field OperationsSep 15Sale14.0137,000518,37031,500Sep 17 05:14 PM
Hennessy SeamusChief Financial OfficerSep 11Option Exercise0.2025,0005,00045,666Sep 12 05:56 PM
Hennessy SeamusChief Financial OfficerSep 11Sale15.0425,000375,90820,666Sep 12 05:56 PM
TickerVHC [AMEX]
CompanyVirnetX Holding Corp
IndustryInternet Software & Services
Market Cap277.96MEPS (ttm)-0.50
P/E-EPS this Y-1.90%
Forward P/E15.40EPS next Y-77.71%
PEG-EPS past 5Y-9.10%
P/S115.82EPS next 5Y15.00%
P/B11.00EPS Q/Q7.10%
Dividend-Sales Q/Q4366.70%
Insider Own15.70%Inst Own29.50%
Insider Trans4.24%Inst Trans-6.62%
Short Float40.40%EarningsMay 09
Analyst Recom2.00Target Price42.33
Avg Volume1.07M52W Range4.18 - 25.49
19-Sep-14 09:27AM9:27 am VirnetX Holding: USPTO terminates patent reexamination proceedings against VHC Briefing.com
19-Sep-14 09:26AMUSPTO Terminates Patent Reexamination Proceedings against VirnetX PR Newswire
18-Sep-14 02:47PMWhy VirnetX (VHC) Stock Plummeted to a One-Year Low Today at TheStreet
18-Sep-14 02:35PM[video] VirnetX plummets at CNBC
18-Sep-14 02:35PMVirnetX plummets CNBC
18-Sep-14 01:20PMVirnetX Investor Conference Call PR Newswire
18-Sep-14 12:51PMVirnetX Holding downgraded by Gilford Securities Briefing.com
17-Sep-14 02:30PMVirnetX Down as Court Overrules Patent Award from Apple Zacks
17-Sep-14 07:41AMWeakness Seen in VirnetX Holding (VHC): Stock Tanks 44.4% Zacks
16-Sep-14 05:45PMStock Pops & Drops: VHC, ACI, X, DKS CNBC
VirnetX Holding Corporation develops software and technology solutions for securing real-time communications over the Internet. The company's software and technology solutions include secure domain name registry and GABRIEL Connection Technology that are designed to secure various real-time communications over the Internet, as well as enable organizations and individuals to establish communities of secure, registered users, and transmit information between various devices, networks, and operating systems. These secure network communities are designed to support content applications, such as Instant messaging, voice over Internet protocol, mobile services, streaming video, file transfer, remote desktop, and Mobile-to-Mobile communications in a secure environment. It also intends to provide a portfolio of licenses and services comprising VirnetX technology; GABRIEL Connection Technology software development kit, including object libraries, sample code, testing and quality assurance tools, and supporting documentation required by customers to implement the company's technology; domain name registrar service; registrar server software; connection server software; and relay server software, as well as technical support, and secure domain name master registry and connection services. The company serves developers and original equipment manufacturers of chips, servers, smart phones, tablets, e-Readers, laptops, net books, and other devices in the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets. VirnetX Holding Corporation was incorporated in 2005 and is based in Zephyr Cove, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Feiner GaryDirectorSep 18Sale5.0025,100125,5000Sep 19 09:14 PM
Larsen KendallPresident & CEOSep 18Sale4.461,750,0007,805,0006,181,526Sep 19 09:12 PM
Short Robert D IIIDirectorMay 14Buy13.803,50048,30030,166May 15 10:00 AM
Larsen KendallPresident & CEOMar 26Option Exercise0.24249,09660,007274,929Mar 26 08:04 PM
Angelo Michael FDirectorMar 03Sale22.971,26128,96525,589Mar 05 03:47 PM
CompanyReceptos, Inc.
Market Cap1.74BEPS (ttm)-3.72
P/E-EPS this Y69.20%
Forward P/E-EPS next Y18.10%
PEG-EPS past 5Y0.00%
P/S386.95EPS next 5Y-
P/B9.60EPS Q/Q81.50%
Dividend-Sales Q/Q-6.70%
Insider Own0.10%Inst Own-
Insider Trans-98.67%Inst Trans-
Short Float9.70%EarningsAug 12/b
Analyst Recom1.60Target Price65.80
Avg Volume481.53K52W Range20.90 - 65.47
15-Sep-14 08:19AMUPDATE: Credit Suisse Reiterates On Receptos Inc Ahead Of Investor Call Benzinga
15-Sep-14 08:05AMRECEPTOS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
10-Sep-14 02:53PMStocks Hold Modest Gains; FleetCor Reverses Higher at Investor's Business Daily
10-Sep-14 01:25PMStocks Turn Higher After Soft Start; U.S. Silica Jumps at Investor's Business Daily
10-Sep-14 01:24PMFraud Allegations Cause 21Vianet Group To Plunge at TheStreet
10-Sep-14 11:58AMReceptos MS Drug Yields More Good Data; Stock Jumps at Investor's Business Daily
10-Sep-14 08:00AMReceptos Announces Oral Podium Presentation at MS Boston 2014 GlobeNewswire
29-Aug-14 11:53AM4 Biotechs That Might Be Bought Soon at Investor's Business Daily
27-Aug-14 10:25AMBiotech Investors Arch Venture Partners Raise $400 Million New Fund To Bet On 'Wild Ideas' at Forbes
25-Aug-14 10:00AMReceptos (RCPT) Flagged As Strong On High Volume at TheStreet
Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that are in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Torres S. EdwardDirectorSep 19Sale62.55169,57010,606,6041,067,067Sep 19 09:03 PM
Torres S. EdwardDirectorSep 18Sale62.7791,5135,744,2711,236,637Sep 19 09:03 PM
HINKLE DAVID ASr. Dir. Fin.,Controller & CAOSep 17Option Exercise11.182,00022,3601,375Sep 18 09:01 PM
Torres S. EdwardDirectorSep 17Sale63.6738,9172,477,8451,328,150Sep 19 09:03 PM
HINKLE DAVID ASr. Dir. Fin.,Controller & CAOSep 17Sale64.822,000129,6400Sep 18 09:01 PM
CompanyTiVo Inc.
IndustryCATV Systems
Market Cap1.55BEPS (ttm)0.26
P/E51.42EPS this Y-86.50%
Forward P/E32.85EPS next Y48.54%
PEG4.63EPS past 5Y14.20%
P/S3.49EPS next 5Y11.10%
P/B3.00EPS Q/Q-95.90%
Dividend-Sales Q/Q11.80%
Insider Own2.90%Inst Own84.60%
Insider Trans8.27%Inst Trans-1.50%
Short Float3.95%EarningsAug 26/a
Analyst Recom2.30Target Price16.05
Avg Volume1.44M52W Range11.31 - 14.29
18-Sep-14 01:40PMTiVo's $200M Convertible Notes to Fund Share Buyback Zacks
18-Sep-14 12:27PM[$$] TiVo Shows Some Smart Moves at Barrons.com
18-Sep-14 07:00AMTiVo: Gotham and NCIS: New Orleans Most Anticipated Fall TV Dramas Marketwired
17-Sep-14 10:35AMHow Will TiVo (TIVO) Stock React to Convertible Senior Notes Sale? at TheStreet
17-Sep-14 08:43AMTIVO INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
17-Sep-14 08:03AM8:03 am TiVo priced a private offering of $200 mln 2% convertible senior notes; majority of proceeds to fund share repurchases; repurchases are separate from previously announced $350 mln share repurchase program Briefing.com
17-Sep-14 08:00AMTiVo Announces Pricing of Private Offering of $200 Million 2% Convertible Senior Notes Marketwired
17-Sep-14 04:14AMVirgin Media's TiVo design makeover begins with an updated iOS app at Engadget
16-Sep-14 08:48AMTIVO INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
15-Sep-14 04:25PMHow Will TiVo (TIVO) Stock React To Filing Of $200 Million In Senior Notes? at TheStreet
TiVo Inc. provides software, services, and technology that enable the distribution and management of video content through set-top boxes (STBs), and smartphones and tablets primarily in the United States. It offers whole-home solutions that include 4-Tuner and 6-Tuner digital video recorders (DVRs)/gateways, IP STBs, and streaming to mobile and tablet iOS devices with features, such as What to Watch Now, Season Pass recordings, integrated search, access to broadband video content, TiVo online/mobile scheduling, and applications on tablet computers and smartphones. As of January 31, 2014, the company had 4.2 million subscriptions to the TiVo service through its TiVo-Owned and television service operators (MSO) businesses. It also provides short- and long-form interactive video advertising, lead generation, and commerce, as well as second-by-second audience research measurement solutions that combine television and Internet viewing data with purchase activity or demographic attributes; and engineering professional services in connection with the development and deployment of the TiVo service to its MSO customers. The company distributes TiVo DVR through consumer electronics retailers and its on-line store at TiVo.com; and offers TiVo service through agreements with satellite and cable television service providers and broadcasters on MSO provisioned STBs and other devices. The company was founded in 1997 and is headquartered in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klugman Jeffrey LEVP Product & RevenueSep 18Sale13.606,45487,769158,759Sep 19 08:54 PM
ROGERS THOMAS SPresident and CEOAug 28Option Exercise6.5276,685499,9861,921,201Sep 02 07:11 PM
Klugman Jeffrey LEVP Product & RevenueJul 03Sale13.322,26230,130172,259Jul 03 03:34 PM
CHOPRA NAVEEN K.CFOJul 01Sale12.982,26229,354404,450Jul 03 03:35 PM
Klugman Jeffrey LEVP Product & RevenueJul 01Sale12.993,00038,970174,521Jul 03 03:34 PM
CompanyUnited Therapeutics Corporation
IndustryDrug Manufacturers - Other
Market Cap6.15BEPS (ttm)5.10
P/E25.51EPS this Y-42.60%
Forward P/E13.22EPS next Y15.99%
PEG5.10EPS past 5Y38.20%
P/S5.11EPS next 5Y5.00%
P/B5.11EPS Q/Q38.20%
Dividend-Sales Q/Q15.00%
Insider Own0.10%Inst Own96.90%
Insider Trans-3.28%Inst Trans-3.96%
Short Float10.43%EarningsJul 29/b
Analyst Recom2.40Target Price114.79
Avg Volume805.62K52W Range76.02 - 131.28
17-Sep-14 07:30AMAxsome Therapeutics Announces Appointments to Its Board of Directors GlobeNewswire
16-Sep-14 03:00AMPluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market GlobeNewswire
15-Sep-14 05:32PMToday's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
09-Sep-14 03:50PMPluristem & United Therapeutics Progress with Phase I Study Zacks
02-Sep-14 05:25PMUnited Therapeutics Soars on Remodulin Patent Case Win Zacks
02-Sep-14 07:58AMUnited Therapeutics (UTHR) Shares March Higher, Can It Continue? Zacks
29-Aug-14 04:21PMUnited Therapeutics Legal Victory Sends Stock Flying at Investor's Business Daily
29-Aug-14 02:21PMUnited Therapeutics Up 27% as Patent Win 'Close to a Best Case Scenario' at Barrons.com
29-Aug-14 02:02PMUnited Therapeutics rises on drug-patent ruling AP
29-Aug-14 12:49PMDistrict Court Decision Received In Remodulin Patent Case PR Newswire
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JEFFS ROGERPresident & COOSep 19Option Exercise30.7510,000307,50011,234Sep 19 08:19 PM
JEFFS ROGERPresident & COOSep 19Sale129.6010,0001,296,0001,234Sep 19 08:19 PM
ROTHBLATT MARTINE ACEOSep 18Option Exercise32.379,662312,7855,687Sep 18 09:06 PM
Ferrari John MaximCFOSep 18Option Exercise50.0910,000500,90010,407Sep 18 09:10 PM
ROTHBLATT MARTINE ACEOSep 18Sale127.359,6621,230,409140Sep 18 09:06 PM
CompanyScience Applications International Corporation
IndustryInformation Technology Services
Market Cap2.15BEPS (ttm)2.50
P/E18.30EPS this Y-39.00%
Forward P/E14.27EPS next Y12.18%
PEG3.66EPS past 5Y0.00%
P/S0.55EPS next 5Y5.00%
P/B5.97EPS Q/Q37.30%
Dividend2.45%Sales Q/Q-7.90%
Insider Own1.40%Inst Own57.60%
Insider Trans15.63%Inst Trans5.87%
Short Float3.15%EarningsSep 09/a
Analyst Recom2.60Target Price48.33
Avg Volume335.99K52W Range28.53 - 47.96
16-Sep-14 12:03PMCourt Vacates VirnetX Holding Corporation Patent Victory Against Apple Inc., Shares Plummet 50% Benzinga
10-Sep-14 06:00AMSCIENCE APPLICATIONS INTERNATIONAL CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
09-Sep-14 05:05PM[$$] Science Applications Revenue Declines at The Wall Street Journal
09-Sep-14 04:43PMAfter-hours buzz: Apple, Krispy Kreme Doughnuts & more at CNBC
09-Sep-14 04:24PMSCIENCE APPLICATIONS INTERNATIONAL CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial EDGAR Online
09-Sep-14 04:05PMSAIC Announces Financial Results for the Second Quarter of Fiscal Year 2015 PR Newswire
09-Sep-14 03:23PMPalo Alto Networks, Krispy Kreme in focus at MarketWatch
09-Sep-14 07:07AMQ2 2015 SAIC Earnings Release - After Market Close CCBN
08-Sep-14 04:30PMSAIC Awarded $408 Million Blanket Purchase Agreement by GSA FEDSIM On Behalf Of DoD PR Newswire
Science Applications International Corporation provides technical, engineering, and enterprise information technology (IT) services in the United States. Its technical and engineering solutions include engineering and maintenance of ground and maritime systems, logistics, training, and simulation, as well as operation and program support services. The company's enterprise IT solutions comprise end-to-end enterprise IT services, including the design, development, integration, deployment, management and operation, sustainment, and security of the clients IT infrastructure. It serves the U.S. Military comprising Army, Air Force, Navy, and Marines; the U.S. Defense Logistics Agency; the National Aeronautics and Space Administration; the U.S. Department of State; and the U.S. Department of Homeland Security. The company was formerly known as SAIC Gemini, Inc. and changed its name to Science Applications International Corporation in September 2013. Science Applications International Corporation was founded in 1969 and is headquartered in McLean, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WAGONER DOUGLAS MARTINSector PresidentSep 17Sale46.216,902318,9434,026Sep 19 08:03 PM
Hartley John RobertChief Financial OfficerJun 26Option Exercise30.2433,6271,016,91599,489Jun 30 05:43 PM
KEENAN BRIAN FExec VP for Human ResourcesJun 16Option Exercise30.9744,8381,388,65054,590Jun 18 06:18 PM
Hartley John RobertChief Financial OfficerJun 16Option Exercise35.7621,770778,41984,763Jun 18 06:18 PM
KEENAN BRIAN FExec VP for Human ResourcesApr 15Option Exercise35.7635,5581,271,43043,622Apr 17 08:53 PM
CompanyKaryopharm Therapeutics, Inc.
IndustryDrugs - Generic
Market Cap1.29BEPS (ttm)-2.06
P/E-EPS this Y-863.80%
Forward P/E-EPS next Y-35.20%
PEG-EPS past 5Y0.00%
P/S6463.76EPS next 5Y23.70%
P/B8.91EPS Q/Q-120.00%
Dividend-Sales Q/Q-84.20%
Insider Own4.50%Inst Own53.70%
Insider Trans-29.32%Inst Trans42.55%
Short Float16.00%EarningsAug 07
Analyst Recom1.80Target Price55.67
Avg Volume269.95K52W Range15.50 - 47.98
09-Sep-14 06:30AMKaryopharm Announces Three Clinical Data Presentations at ESMO 2014 GlobeNewswire
15-Aug-14 01:04PMKARYOPHARM THERAPEUTICS INC. Financials EDGAR Online Financials
08-Aug-14 04:51PMCFO Moves: Karyopharm, Education Realty Trust at The Wall Street Journal
08-Aug-14 07:45AMKARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EDGAR Online
08-Aug-14 07:30AMKaryopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer GlobeNewswire
07-Aug-14 04:17PMKaryopharm to Present at the Wedbush 2014 Life Sciences Management Access Conference GlobeNewswire
07-Aug-14 07:07AMQ2 2014 Karyopharm Therapeutics Inc Earnings Release - Time Not Supplied CCBN
07-Aug-14 07:00AMKARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
07-Aug-14 07:00AMKaryopharm Therapeutics Reports Second Quarter Financial Results for 2014 GlobeNewswire
01-Aug-14 04:05PMKaryopharm to Host Second Quarter 2014 Earnings Call on August 7, 2014 GlobeNewswire
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate, Selinexor, a novel selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, an oral SINE compound that is in Phase 2b clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Czernik Marcin10% OwnerSep 18Sale40.162,778111,5562,923,015Sep 19 07:52 PM
Czernik Marcin10% OwnerSep 17Sale40.269,569385,2702,925,793Sep 19 07:52 PM
Chione Ltd10% OwnerSep 12Sale41.124,312177,32510,223,767Sep 16 07:47 PM
Czernik Marcin10% OwnerSep 04Sale38.0712,795487,0952,971,358Sep 08 09:13 PM
Czernik Marcin10% OwnerAug 27Sale39.0721,460838,4312,984,153Aug 28 09:36 PM
CompanyMicrosemi Corporation
IndustrySemiconductor - Integrated Circuits
Market Cap2.45BEPS (ttm)0.05
P/E513.00EPS this Y237.10%
Forward P/E9.19EPS next Y27.50%
PEG41.04EPS past 5Y-5.00%
P/S2.25EPS next 5Y12.50%
P/B2.24EPS Q/Q-125.00%
Dividend-Sales Q/Q20.50%
Insider Own0.40%Inst Own98.00%
Insider Trans-1.29%Inst Trans0.98%
Short Float3.59%EarningsJul 24/a
Analyst Recom1.60Target Price31.88
Avg Volume355.48K52W Range20.22 - 27.91
17-Sep-14 04:15PMMicrosemi Corporation Unit Closes Centellax Acquisition Zacks
16-Sep-14 04:02PMMicrosemi Corporation Completes Successful Acquisition of Centellax PR Newswire
12-Sep-14 08:20AMMicrosemi Declares $100M Buyback: Are you Considering? Zacks
11-Sep-14 05:40PMMicrosemi to Buy Centellax for Communications Products Zacks
10-Sep-14 04:21PMMICROSEMI CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
10-Sep-14 07:00AMMicrosemi Corporation Announces $100 Million Stock Repurchase Program PR Newswire
10-Sep-14 07:00AMMicrosemi To Acquire Centellax PR Newswire
04-Sep-14 07:00AMMicrosemi Introduces Timberwolf, an Innovative Programmable DSP Platform Enabling Leading Solutions for the Intelligent Processing Markets PR Newswire
03-Sep-14 07:00AMMicrosemi Strengthens its Timing Products Leadership with New Any-to-any Frequency Clock Multiplier and Jitter Attenuator Clock Management Products PR Newswire
13-Aug-14 07:00AMMicrosemi SmartFusion2 and IGLOO2 Product Families are First and Only FPGAs in the PLD Industry to Successfully Complete NSA Information Assurance Directorate Secure Implementation Guidelines Document PR Newswire
Microsemi Corporation designs, manufactures, and markets analog and mixed-signal semiconductor solutions primarily in the United States, Europe, and Asia. Its products include radio frequency (RF) and power components, analog and RF integrated circuits, system-on-chip (SoC) solutions, timing and synchronization products, chip-scale atomic clocks, field programmable gate arrays (FPGAs), voice line circuits, security technology, and high-reliability ICs and discrete components. The company also offers subsystems and modules that include application-specific power modules, infrastructure time generation, distribution and synchronization systems, and Power-over-Ethernet (PoE) midspans. It primarily serves aerospace, communications, defense and security, and industrial markets. The company's products are used in wireless and wired LAN systems, communications infrastructure systems, pacemakers and defibrillators, missile systems, military and commercial satellites and aircrafts, oil field equipment, and airport security systems. Microsemi Corporation markets its products directly, as well as through electronic component distributors and independent sales representatives. The company was formerly known as Microsemiconductor Corporation and changed its name to Microsemi Corporation in February 1983. Microsemi Corporation was founded in 1960 and is headquartered in Aliso Viejo, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEIBEL DENNIS RLead Independent DirectorSep 17Option Exercise16.156,00096,90018,925Sep 19 07:30 PM
LEIBEL DENNIS RLead Independent DirectorSep 17Sale25.896,000155,34512,925Sep 19 07:30 PM
PETERSON JAMES JChairman of the Board & CEOSep 16Option Exercise13.729,036123,974316,687Sep 17 07:36 PM
PETERSON JAMES JChairman of the Board & CEOSep 16Sale25.749,036232,545307,651Sep 17 07:36 PM
LITCHFIELD STEVEN GEVP & Chief Strategy OfficerSep 15Option Exercise13.7232,602447,299119,844Sep 17 07:37 PM
CompanyRevance Therapeutics, Inc.
Market Cap473.32MEPS (ttm)-1.78
P/E-EPS this Y-28.40%
Forward P/E-EPS next Y-8.90%
PEG-EPS past 5Y0.00%
P/S676.18EPS next 5Y-
P/B1.97EPS Q/Q22.50%
Dividend-Sales Q/Q-
Insider Own1.20%Inst Own73.80%
Insider Trans131.28%Inst Trans36.46%
Short Float5.48%EarningsAug 12/a
Analyst Recom2.00Target Price45.33
Avg Volume208.00K52W Range20.11 - 39.86
02-Sep-14 04:10PMRevance Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
29-Aug-14 04:37PMREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online
22-Aug-14 01:04PMREVANCE THERAPEUTICS, INC. Financials EDGAR Online Financials
13-Aug-14 05:23PMREVANCE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
12-Aug-14 04:15PMREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
12-Aug-14 04:10PMRevance Therapeutics Releases Second Quarter 2014 Financial Results GlobeNewswire
12-Aug-14 04:01PMRevance Therapeutics Appoints Industry Veteran Arthur P. Bertolino, M.D., Ph.D., M.B.A. as Chief Medical Officer GlobeNewswire
12-Aug-14 07:07AMQ2 2014 Revance Therapeutics Inc Earnings Release - After Market Close CCBN
29-Jul-14 04:02PMRevance Therapeutics to Release Second Quarter 2014 Financial Results and Host Conference Call on Tuesday, August 12, 2014 GlobeNewswire
24-Jun-14 04:05PMRevance Therapeutics Announces Closing of Its Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waugh JacobChief Scientific OfficerSep 17Option Exercise7.7669,380538,386122,713Sep 19 07:22 PM
BYRNES ROBERT FDirectorSep 17Option Exercise3.602,6669,5982,666Sep 19 07:26 PM
Waugh JacobChief Scientific OfficerSep 17Sale20.7397,7132,025,44125,000Sep 19 07:22 PM
CompanyRE/MAX Holdings, Inc.
IndustryProperty Management
Market Cap350.76MEPS (ttm)0.68
P/E44.54EPS this Y-
Forward P/E18.91EPS next Y8.98%
PEG4.95EPS past 5Y15.10%
P/S2.13EPS next 5Y9.00%
P/B1.42EPS Q/Q-
Dividend0.83%Sales Q/Q7.90%
Insider Own1.00%Inst Own96.20%
Insider Trans-27.99%Inst Trans2.03%
Short Float3.82%EarningsAug 13/a
Analyst Recom2.00Target Price33.00
Avg Volume74.80K52W Range25.29 - 33.39
16-Sep-14 12:58PMFewer Home Sales, Slower Price Increases PR Newswire
15-Sep-14 11:30AMEssential Tips For Buying A HUD Home at Investopedia
15-Sep-14 08:00AMRE/MAX of Southeastern Michigan Announces New Chairman, CEO PR Newswire
11-Sep-14 02:04PMRE/MAX Agents Receive 14 Million Leads PR Newswire
09-Sep-14 06:55AMHow RE/MAX Holdings Stock Stands Out in a Strong Industry Zacks
08-Sep-14 09:42AMMoving Average Crossover Alert: RE/MAX (RMAX) Zacks
26-Aug-14 01:17PMRE/MAX Launches National Sweepstakes PR Newswire
22-Aug-14 01:04PMRE/MAX HOLDINGS, INC. Financials EDGAR Online Financials
18-Aug-14 04:29PMRE/MAX Sees Opportunity in Recovering Market PR Newswire
14-Aug-14 05:36PMThe Roses in the Market... Yahoo Finance Blogs
RE/MAX Holdings, Inc. operates as a franchisor for residential and commercial real estate brokerage services in the United States and internationally. It operates in two segments, Real Estate Franchise Services, and Brokerage and Other. The company offers its real estate franchise services under the RE/MAX brand name. It also provides real estate brokerage services in the United States. The company was founded in 1973 and is headquartered in Denver, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Margaret M.Chief Executive OfficerSep 18Option Exercise3.604,00014,40049,455Sep 19 07:18 PM
Kelly Margaret M.Chief Executive OfficerSep 18Sale30.934,000123,72045,455Sep 19 07:18 PM
Kelly Margaret M.Chief Executive OfficerSep 17Option Exercise3.604,50016,20049,955Sep 17 07:42 PM
Kelly Margaret M.Chief Executive OfficerSep 17Sale30.644,500137,88045,455Sep 17 07:42 PM
Kelly Margaret M.Chief Executive OfficerSep 15Option Exercise3.606,50023,40051,955Sep 17 07:42 PM
1 2 3 4 5 6 7 8 9 10 next